01494nam a2200289   4500001000800000005001700008007000300025008004100028040000800069041000800077100003200085245005500117300002500172520058600197650001800783650003300801650003300834650003400867650004400901650003600945650001700981650002500998650002301023773011001046942003101156999001701187ESSALUD20260902163508.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aLundberg, Ingrid E. 954489  aA Phase 3 Trial of brepocitinib in dermatomyositis  apáginas: 1953-1955  aDermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares.  aALERGIA97055  aINMUNOLOGÍA GENERAL953664  aENFERMEDAD AUTOINMUNE953665  aDERMATOLOGÍA GENERAL954449  aENFERMEDAD PULMONAR INTERSTICIAL953691  aENFERMEDAD NEUROMUSCULAR953763  aNEUROLOGÍA  aNEUROCIRUGÍA97782  aCÉLULAS T9540970 022717922669dMassachusetts NEJM GroupoNEJM014tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-31zsqb  c22907d22907